Regenxbio Shares Dip 6.8% to $6.68 Amid Gene‑Therapy Milestone Outlook
RGENXBIO (RGNX) dips 6.8% to $6.68 as investors eye upcoming gene‑therapy milestones and partnership talks amid sector‑wide softness.
3 minutes to read
REGENXBIO INC
Regenxbio (RGNX) Grows 3.5% to $7.17 – Market Cap $472M & Gene‑Therapy Outlook
Regenxbio (RGNX) shares rise 3.5% amid solid biotech peer gains, trading near 200‑day SMA and close to historic highs – see market insights.
2 minutes to read